Christine Colie1, Katherine G Michel2, Leslie S Massad3, Cuiwei Wang2, Gypsyamber DʼSouza4, Lisa Rahangdale5, Lisa Flowers6, Joel Milam7, Joel M Palefsky8, Howard Minkoff9, Howard D Strickler10, Seble G Kassaye2. 1. Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, DC. 2. Department of Medicine, Georgetown University, Washington, DC. 3. Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 5. Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC. 6. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA. 7. Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 8. Department of Medicine, University of California, San Francisco, CA. 9. Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY. 10. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Abstract
OBJECTIVE: To evaluate the natural history of treated and untreated cervical intraepithelial neoplasia-2 (CIN2) among HIV-positive women. METHODS: Participants were women enrolled in the Women's Interagency HIV Study between 1994 and 2013. One hundred four HIV-positive women diagnosed with CIN2 before age 46 were selected, contributing 2076 visits over a median of 10 years (interquartile range 5-16). The outcome of interest was biopsy-confirmed CIN2 progression, defined as CIN3 or invasive cervical cancer. CIN2 treatment was abstracted from medical records. RESULTS: Most women were African American (53%), current smokers (53%), and had a median age of 33 years at CIN2 diagnosis. Among the 104 HIV-positive women, 62 (59.6%) did not receive CIN2 treatment. Twelve HIV-positive women (11.5%) showed CIN2 progression to CIN3; none were diagnosed with cervical cancer. There was no difference in the median time to progression between CIN2-treated and CIN2-untreated HIV-positive women (2.9 vs. 2.7 years, P = 0.41). CIN2 treatment was not associated with CIN2 progression in multivariate analysis (adjusted hazard ratio 1.82; 95% confidence interval: 0.54 to 7.11), adjusting for combination antiretroviral therapy and CD4 T-cell count. In HIV-positive women, each increase of 100 CD4 T cells was associated with a 33% decrease in CIN2 progression (adjusted hazard ratio 0.67; 95% confidence interval: 0.47 to 0.88), adjusting for CIN2 treatment and combination antiretroviral therapy. CONCLUSIONS: CIN2 progression is uncommon in this population, regardless of CIN2 treatment. Additional studies are needed to identify factors to differentiate women at highest risk of CIN2 progression.
OBJECTIVE: To evaluate the natural history of treated and untreated cervical intraepithelial neoplasia-2 (CIN2) among HIV-positive women. METHODS: Participants were women enrolled in the Women's Interagency HIV Study between 1994 and 2013. One hundred four HIV-positive women diagnosed with CIN2 before age 46 were selected, contributing 2076 visits over a median of 10 years (interquartile range 5-16). The outcome of interest was biopsy-confirmed CIN2 progression, defined as CIN3 or invasive cervical cancer. CIN2 treatment was abstracted from medical records. RESULTS: Most women were African American (53%), current smokers (53%), and had a median age of 33 years at CIN2 diagnosis. Among the 104 HIV-positive women, 62 (59.6%) did not receive CIN2 treatment. Twelve HIV-positive women (11.5%) showed CIN2 progression to CIN3; none were diagnosed with cervical cancer. There was no difference in the median time to progression between CIN2-treated and CIN2-untreated HIV-positive women (2.9 vs. 2.7 years, P = 0.41). CIN2 treatment was not associated with CIN2 progression in multivariate analysis (adjusted hazard ratio 1.82; 95% confidence interval: 0.54 to 7.11), adjusting for combination antiretroviral therapy and CD4 T-cell count. In HIV-positive women, each increase of 100 CD4 T cells was associated with a 33% decrease in CIN2 progression (adjusted hazard ratio 0.67; 95% confidence interval: 0.47 to 0.88), adjusting for CIN2 treatment and combination antiretroviral therapy. CONCLUSIONS: CIN2 progression is uncommon in this population, regardless of CIN2 treatment. Additional studies are needed to identify factors to differentiate women at highest risk of CIN2 progression.
Authors: Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur Journal: Arch Pathol Lab Med Date: 2012-06-28 Impact factor: 5.534
Authors: Christina Carlander; Philippe Wagner; Veronica Svedhem; Kristina Elfgren; Katarina Westling; Anders Sönnerborg; Pär Sparén Journal: Int J Cancer Date: 2016-06-02 Impact factor: 7.396
Authors: David H Adler; Lisa Kakinami; Tebogo Modisenyane; Nkeko Tshabangu; Lerato Mohapi; Guy De Bruyn; Neil A Martinson; Tanvier Omar Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: L S Massad; L Ahdieh; L Benning; H Minkoff; R M Greenblatt; H Watts; P Miotti; K Anastos; M Moxley; L I Muderspach; S Melnick Journal: J Acquir Immune Defic Syndr Date: 2001-08-15 Impact factor: 3.731
Authors: Nora A Danhof; Esme I Kamphuis; Jacqueline Limpens; Luc R C W van Lonkhuijzen; Eva Pajkrt; Ben W J Mol Journal: Eur J Obstet Gynecol Reprod Biol Date: 2015-03-02 Impact factor: 2.435
Authors: Howard Minkoff; Ye Zhong; Robert D Burk; Joel M Palefsky; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Rodney L Wright; Christine Colie; Gypsyamber D'Souza; L Stewart Massad; Howard D Strickler Journal: J Infect Dis Date: 2010-03 Impact factor: 5.226